Proliferative Diabetic Retinopathy clinical trials

Explore recruiting proliferative diabetic retinopathy clinical trials.

Recruiting proliferative diabetic retinopathy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Proliferative Diabetic Retinopathy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes (FOCUS)

Portugal, Poland, Spain, Romania, Czechia, Germany +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multicentric, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of COLIRIOBCN070660 administered topically in patients with moderately severe to severe non-proliferative diabetic retinopathy

Spain

Phase II and Phase III (Integrated) EU CTIS Study details

A study to learn more about how BAY3283142 moves into, through, and out of the body of healthy participants when taken together with atazanavir and to assess the proportion of BAY3283142 that reaches the blood when taken by mouth.

Netherlands

Human Pharmacology (Phase I)- Other EU CTIS Study details

(22040 ALPINE 1) A Phase 2b dose-finding, randomized, placebo-controlled, double-blind study to evaluate efficacy and safety of BAY 3283142 on top of standard of care in reducing albuminuria in patients with chronic kidney disease

Belgium, Sweden, Spain, Italy, Portugal, Slovakia +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72 week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderate to severe non-proliferative diabetic retinopathy

Hungary, Spain, Italy, Germany, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Proliferative Diabetic Retinopathy trials by city

Proliferative Diabetic Retinopathy in Toronto Proliferative Diabetic Retinopathy in Vancouver Proliferative Diabetic Retinopathy in Montreal Proliferative Diabetic Retinopathy in Calgary Proliferative Diabetic Retinopathy in Edmonton Proliferative Diabetic Retinopathy in Ottawa Proliferative Diabetic Retinopathy in Winnipeg Proliferative Diabetic Retinopathy in Quebec City Proliferative Diabetic Retinopathy in Hamilton Proliferative Diabetic Retinopathy in Kitchener Proliferative Diabetic Retinopathy in London Proliferative Diabetic Retinopathy in Halifax Proliferative Diabetic Retinopathy in New York Proliferative Diabetic Retinopathy in Los Angeles Proliferative Diabetic Retinopathy in Chicago Proliferative Diabetic Retinopathy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease